|
HOLLIS-EDEN PHARM, (HEPH) Stock Research Free Stock Rating
|
|
| |
| Company Profile |
| |
|
Hollis-Eden Pharmaceuticals, Inc. (HeP), a development stage pharmaceutical company, engages in the discovery, development, and commercialization of products, for the treatment of diseases and disorders, in which the body is unable to mount an appropriate immune response. The companys development efforts focus on radiation and chemotherapy induced immune suppression and immune dysregulation caused by infectious diseases, such as HIV, malaria, and tuberculosis. In addition, Hollis-Eden is developing a nonimmune regulating hormone drug candidate for providing protection against DNA mutations from radiation exposure and chemotherapy treatment. HeP was founded by Richard B. Hollis in 1994. It was formerly known as Initial Acquisition Corp and changed its name to Hollis-Eden Pharmaceuticals, Inc. in 1997. The company is headquartered in San Diego, California.
|
|
